Longeveron Announces Closing of Private Placement of up to $30 Million
Globe Newswire (Wed, 11-Mar 4:05 PM ET)
3 Penny Stocks to Watch Now, 3/11/26
TipRanks (Wed, 11-Mar 10:11 AM ET)
Longeveron’s $30M Private Placement Extends Cash Runway Beyond Key Clinical Milestone
Market Chameleon (Tue, 10-Mar 5:54 AM ET)
Longeveron Announces Private Placement of up to $30 Million
Globe Newswire (Tue, 10-Mar 9:00 AM ET)
Globe Newswire (Wed, 25-Feb 11:05 AM ET)
Longeveron Appoints Stephen H. Willard as Chief Executive Officer
Globe Newswire (Fri, 13-Feb 4:30 PM ET)
Globe Newswire (Thu, 5-Feb 9:15 AM ET)
Globe Newswire (Thu, 29-Jan 9:15 AM ET)
Globe Newswire (Mon, 26-Jan 9:15 AM ET)
Globe Newswire (Mon, 29-Dec 9:15 AM ET)
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
Longeveron - Class A trades on the NASDAQ stock market under the symbol LGVN.
As of March 11, 2026, LGVN stock price declined to $0.81 with 4,566,572 million shares trading.
LGVN has a beta of 0.76, meaning it tends to be less sensitive to market movements. LGVN has a correlation of 0.01 to the broad based SPY ETF.
LGVN has a market cap of $17.33 million. This is considered a Sub-Micro Cap stock.
Last quarter Longeveron - Class A reported $137,000 in Revenue and -$.39 earnings per share. This fell short of revenue expectation by $-145,802 and missed earnings estimates by -$.14.
In the last 3 years, LGVN traded as high as $44.00 and as low as $.48.
The top ETF exchange traded funds that LGVN belongs to (by Net Assets): VTI, VXF.
LGVN has underperformed the market in the last year with a return of -44.7%, while SPY returned +21.9%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in LGVN shares. However, LGVN has outperformed the market in the last 3 month and 2 week periods, returning +29.5% and +39.8%, while SPY returned -1.3% and -1.6%, respectively. This indicates LGVN has been having a stronger performance recently.
LGVN support price is $.84 and resistance is $.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LGVN shares will trade within this expected range on the day.
